Peptides and growth factors in small cell lung cancer: production, binding sites, and growth effects - PubMed (original) (raw)

Peptides and growth factors in small cell lung cancer: production, binding sites, and growth effects

G Bepler et al. J Cancer Res Clin Oncol. 1988.

Abstract

We investigated the production, binding to cell membranes, and influence on cell proliferation of peptides and growth factors in 4 classic, 5 transitional, and 5 variant SCLC cell lines. Glucagon, neurotensin, and TGF-alpha were present in all cell lines. Bombesin was predominantly found in classic cell lines and insulin in variant cell lines. Neurokinin A, calcitonin, CGRP, GHRF, somatostatin, and CNTF were detectable in some cell lines without prevalence for a particular cell type. We could not detect AVP, growth hormone, neuropeptide Y, substance P, VIP, and NGF. Insulin binding sites were present on 11/14 cell lines, and some cell lines specifically bound bombesin, calcitonin, and EGF. Growth effects were detectable for insulin, GRP-related peptides, tachykinins, and VIP. Using serum-free conditions, insulin and VIP had a growth stimulating effect in liquid culture at nanomolar concentrations. Bombesin and neuromedin B stimulated the clonal growth at a concentration of 3-30 nM. The tachykinins neurokinin A, neurokinin B, physalaemin, and eledoisin inhibited the clonal and mass culture growth with a peak effect in the range of 0.1 to 10 pM. Peptide-induced stimulating and inhibiting effects were within a magnitude of 2-fold. All other peptides and growth factors tested, including ACTH, AVP, calcitonin, glucagon, neurotensin, somatostatin, EGF, CNTF, and NGF did not affect the growth of SCLC. We conclude that the growth of SCLC is partly controlled by such peptides in an autocrine/paracrine fashion.

PubMed Disclaimer

Cited by

Inducible expression of tissue factor in small-cell lung cancer: impact on morphology and matrix metalloproteinase secretion.
Hahn N, Heiden M, Seitz R, Salge-Bartels U. Hahn N, et al. J Cancer Res Clin Oncol. 2012 Apr;138(4):695-703. doi: 10.1007/s00432-011-1139-1. Epub 2012 Jan 12. J Cancer Res Clin Oncol. 2012. PMID: 22237453
Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue.
O'Byrne KJ, Ennis JT, Freyne PJ, Clancy LJ, Prichard JS, Carney DN. O'Byrne KJ, et al. Br J Cancer. 1994 Apr;69(4):762-6. doi: 10.1038/bjc.1994.144. Br J Cancer. 1994. PMID: 7908220 Free PMC article. Clinical Trial.
Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer.
Groves SM, Ildefonso GV, McAtee CO, Ozawa PMM, Ireland AS, Stauffer PE, Wasdin PT, Huang X, Qiao Y, Lim JS, Bader J, Liu Q, Simmons AJ, Lau KS, Iams WT, Hardin DP, Saff EB, Holmes WR, Tyson DR, Lovly CM, Rathmell JC, Marth G, Sage J, Oliver TG, Weaver AM, Quaranta V. Groves SM, et al. Cell Syst. 2022 Sep 21;13(9):690-710.e17. doi: 10.1016/j.cels.2022.07.006. Epub 2022 Aug 17. Cell Syst. 2022. PMID: 35981544 Free PMC article.
Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate.
Noordzij MA, van Steenbrugge GJ, van der Kwast TH, Schröder FH. Noordzij MA, et al. Urol Res. 1995;22(6):333-41. doi: 10.1007/BF00296871. Urol Res. 1995. PMID: 7740652 Review.
Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma.
Kirsch CM, von Pawel J, Grau I, Tatsch K. Kirsch CM, et al. Eur J Nucl Med. 1994 Dec;21(12):1318-25. doi: 10.1007/BF02426696. Eur J Nucl Med. 1994. PMID: 7875170 Clinical Trial.

References

1. J Cancer Res Clin Oncol. 1987;113(3):253-9 - PubMed
1. Recent Results Cancer Res. 1985;99:117-29 - PubMed
1. Peptides. 1987 Jan-Feb;8(1):103-7 - PubMed
1. Exp Cell Res. 1977 Feb;104(2):255-62 - PubMed
1. N Engl J Med. 1978 Jul 20;299(3):105-10 - PubMed

Peptides and growth factors in small cell lung cancer: production, binding sites, and growth effects - PubMed (original) (raw)